Bitcoin Defies Gravity: Grayscale’s Bold Prediction Amid Rate Increase Fears

As the price of Bitcoin (CRYPTO: BTC) experiences fluctuations ahead of the U.S.

As the price of Bitcoin (CRYPTO: BTC) experiences fluctuations ahead of the U.S. Federal Reserve’s upcoming interest rate decision on Wednesday, Grayscale has suggested cryptocurrency prices could still benefit from a rate increase, provided that the outcome aligns with market expectations.

Bitcoin’s price dropped 4.3% on Monday and is currently trading around $27,990, according to TradingView data. However, it recovered from the day’s lows after MicroStrategy reported its results and reaffirmed its strong conviction in its Bitcoin strategy.

Despite falling approximately 1.8% over the past month, the world’s largest cryptocurrency by market capitalization is still up 69% year-to-date.

The Fed is expected to raise rates by 25 basis points, as indicated by CME’s FedWatch tool.

Grayscale analyzed Bitcoin’s volatility, highlighting the turbulence witnessed in the second half of April, and emphasized several key takeaways.

Also Read: ‘Intercompany Chaos’: Bankrupt Crypto Lender Celsius’ UK, US Entities A Facade?

The firm noted, “Bitcoin may still be susceptible to a number of sentiment-driven factors that can be influenced by incorrect or incomplete information,” citing a misleading Arkham alert as an example.

Grayscale also mentioned that the perceived actions of large holders can significantly impact Bitcoin’s value.

Nevertheless, Grayscale maintained factors such as an additional rate hike and declining inflation “align well with a bullish case for Bitcoin in the future.”

The company also points out that the failures of several regional banks demonstrate “investors continue to display an appetite for crypto during times of economic uncertainty.”

Read Next: Bitcoin’s BRC-20 Token Explosion: Market Cap Skyrockets 682% In Just One Week

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Palatin Provides Corporate Update And Highlights Strategic Priorities For Calendar Year 2024; Completed Asset Sale To Cosette Pharmaceuticals For Up To $171M; $12M Upfront Plus Sales-Based Milestones Of Up To $159M

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 StudyData Base Lock 2H January 2024Topline Data Readout Expected Early 1Q Calendar Year 2024Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC

PTN